FDA approves Roche's giredestrant for ESR1-mutated breast cancer
The FDA on Monday approved Roche's giredestrant, marketed as Wilserdly, for patients with HR-positive, HER2-negative advanced breast cancer whose tumors carry an ESR1 mutation.
AI and the frontier tech around it, explained every morning
Stories about Roche · 1 stories
The FDA on Monday approved Roche's giredestrant, marketed as Wilserdly, for patients with HR-positive, HER2-negative advanced breast cancer whose tumors carry an ESR1 mutation.